Double blind trial of nialamide in intermittent claudication. Effects on blood cholesterol, fibrinolysis and 5-hydroxytryptamine.
D001161:Arteriosclerosis / Q000188:drug therapy; D001780:Blood Coagulation Tests; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D004415:Dyspepsia / Q000139:chemically induced; D005342:Fibrinolysis / Q000187:drug effects; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy*; D008995:Monoamine Oxidase / Q000378:metabolism; D009526:Nialamide / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D012701:Serotonin / Q000097:blood; D013919:Thromboangiitis Obliterans / Q000188:drug therapy
D010919:Placebos; D012701:Serotonin; D002784:Cholesterol; D008995:Monoamine Oxidase; D009526:Nialamide